(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company’s poster entitled: “Immune checkpoint modulation by urease-mediated alkalization”, has been accepted for presentation in the
“Checkpoint Blockade Therapy” session at the Third International Cancer lmmunotherapy Conference. The conference is being held in Mainz Germany on September 6th through to the 9th, 2017 at the Rheingoldhalle Congress Center Mainz. Dr. Heman Chao, Helix’s Chief Executive Officer, will be presenting on September 6th, 2017 at 6:00 pm.
Helix-BioPharma-Corp.-CRI-CIMT-EATI-AACR-Presentation-July-31-2017.pdf